Paper42948745PubMed
Remodeling macrophage efferocytosis and phenotype via targeted nanoimmunotherapy for atherosclerosis.
He Z and 15 others. Acta Pharm Sin B, 2026.
Cite this record
ConductScience Library. Remodeling macrophage efferocytosis and phenotype via targeted nanoimmunotherapy for atherosclerosis. Papers, record 42948745. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42948745
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Remodeling macrophage efferocytosis and phenotype via targeted nanoimmunotherapy for atherosclerosis.
- Journal
- Acta Pharm Sin B
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-29
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20080636 | Resolvin D1 binds human phagocytes with evidence for proresolving receptors. | Proc Natl Acad Sci U S A | 2010 | https://conductscience.org/library/papers/20080636 | PubMed |
| 2 | 31222041 | Resolvin D1 promotes the targeting and clearance of necroptotic cells. | Cell Death Differ | 2020 | https://conductscience.org/library/papers/31222041 | PubMed |
| 3 | 41494534 | Restoring immune homeostasis in atherosclerotic plaques via inorganic violet phosphorus nano-immunotherapy. | Cell Rep Med | 2026 | https://conductscience.org/library/papers/41494534 | PubMed |
| 4 | 27437576 | CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. | Nature | 2016 | https://conductscience.org/library/papers/27437576 | PubMed |
| 5 | 32865380 | Colchicine in Patients with Chronic Coronary Disease. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32865380 | PubMed |
| 6 | 35678191 | Theranostic Contribution of Extracellular Matrix Metalloprotease Inducer-Paramagnetic Nanoparticles Against Acute Myocardial Infarction in a Pig Model of Coronary Ischemia-Reperfusion. | Circ Cardiovasc Imaging | 2022 | https://conductscience.org/library/papers/35678191 | PubMed |
| 7 | 30846875 | Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. | Nat Rev Cardiol | 2019 | https://conductscience.org/library/papers/30846875 | PubMed |
| 8 | 39501093 | Nanomedicine-based strategies for the treatment of vein graft disease. | Nat Rev Cardiol | 2025 | https://conductscience.org/library/papers/39501093 | PubMed |
| 9 | 34759324 | Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis. | Nat Rev Cardiol | 2022 | https://conductscience.org/library/papers/34759324 | PubMed |
| 10 | 26284535 | Ultrathin Black Phosphorus Nanosheets for Efficient Singlet Oxygen Generation. | J Am Chem Soc | 2015 | https://conductscience.org/library/papers/26284535 | PubMed |
| 11 | 33472399 | Resolvin D1 Enhances Necroptotic Cell Clearance Through Promoting Macrophage Fatty Acid Oxidation and Oxidative Phosphorylation. | Arterioscler Thromb Vasc Biol | 2021 | https://conductscience.org/library/papers/33472399 | PubMed |
| 12 | 37607320 | Natural Antioxidant-Based Nanodrug for Atherosclerosis Treatment. | Small | 2023 | https://conductscience.org/library/papers/37607320 | PubMed |
| 13 | 8610116 | Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages. | Proc Natl Acad Sci U S A | 1996 | https://conductscience.org/library/papers/8610116 | PubMed |
| 14 | 20133865 | Spatiotemporal controlled delivery of nanoparticles to injured vasculature. | Proc Natl Acad Sci U S A | 2010 | https://conductscience.org/library/papers/20133865 | PubMed |
| 15 | 31822793 | Efferocytosis in health and disease. | Nat Rev Immunol | 2020 | https://conductscience.org/library/papers/31822793 | PubMed |
| 16 | 32718990 | siRNA nanoparticles targeting CaMKIIγ in lesional macrophages improve atherosclerotic plaque stability in mice. | Sci Transl Med | 2020 | https://conductscience.org/library/papers/32718990 | PubMed |
| 17 | 30380386 | CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30380386 | PubMed |
| 18 | 41250788 | Multifunctional Inorganic-Nanosheets-Based Nanohydrogel for Periodontal Bone Regeneration via Antibacterial and Anti-Ferroptotic Immunomodulation. | ACS Appl Mater Interfaces | 2025 | https://conductscience.org/library/papers/41250788 | PubMed |
| 19 | 32004476 | Macrophage Metabolism of Apoptotic Cell-Derived Arginine Promotes Continual Efferocytosis and Resolution of Injury. | Cell Metab | 2020 | https://conductscience.org/library/papers/32004476 | PubMed |
| 20 | 32714754 | Photochemical Activity of Black Phosphorus for Near-Infrared Light Controlled In Situ Biomineralization. | Adv Sci (Weinh) | 2020 | https://conductscience.org/library/papers/32714754 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42948745
GET https://conductscience.org/api/papers/v1/42948745/references?page=2